Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 05 Jul 2017 Planned End Date changed from 13 Apr 2022 to 23 Aug 2024.
- 05 Jul 2017 Planned initiation date changed from 17 Jul 2017 to 30 Oct 2017.
- 10 Jun 2017 Biomarkers information updated